Become an
ISN Member

ISN-ACT Trial List: June 2018
ISN Academy. ISN-ACT . Jun 7, 2018; 219276
Topic: Chronic kidney disease
Disclosure(s): The ISN-Advancing Clinical Trials is a new initiative of the ISN intended to leverage existing infrastructures within ISN, in order to improve global nephrology community participation in clinical trial research. As part of its activities, the ISN-ACT highlights and sometimes analyzes important recent nephrology trials from latest medical literature every month through the ISN-ACT Trial-list. Editors of the ISN-ACT Trial-List also select clinical trials of particular impact, and collaborate with the @ISNeducation social media learning team to represent these trials visually. Join the ISN-ACT To generate more high-quality clinical trials and studies in nephrology, ISN-ACT is calling on investigators and interested individuals. If you are an ISN member interested to join this great initiative, submit your application online. Use the button below (download PDF) to download this month's edition of the list.
Login now to access Regular content available to all registered users.

You may also access ISN content "anytime, anywhere" with the FREE ISN Academy App for iOS and Android.
Discussion Forum (0)
Rate & Comment (0)
Once a month, the ISN-ACT (Advancing Clinical Trials) team collects and publishes a list of important nephrology trials from the latest medical literature. Each trial is reviewed in context and their risk of bias in seven key areas assessed. This month, we looked at the following trials: Mediterranean diet may reduce uraemic metabolites in CKD Nutritional therapy reduces protein carbamylation through urea lowering in chronic kidney disease Di Iorio, et al. Nephrol Dial Transplant. 2018;33(5):804-813 Dietary approaches to reducing serum levels of uraemic toxins are gaining interest. Protein carbamylation is a detrimental chemical modification of serum proteins resulting from high levels of urea. Carbamylation of the amino acid lysine results in formation of homocitrulline – a marker carbamylation associated with adverse cardiovascular outcomes. Di Iorio, et al. randomised 60 participants with CKD stage 3b-4, in a cross-over design, to alternating 6 month periods of a low protein, vegetable rich ‘Mediterranean’ diet (MD) or a very low protein diet (VLPD) (with 3 months control period at the beginning of each phase). Compared with the control period, both diets resulted in lower levels of urea and homocitrulline, with significantly greater reductions in the VLPD group compared with those on MD (urea reduction: 20% versus 67%; [P<0.001]; homocitrulline reduction: 28% versus 41% [P<0.001]). While this study does not provide evidence for improvement in clinical outcomes or quality of life, it does suggest that the urea-lowering effects of low or very low protein diets do result in reductions in uraemic metabolites. The clinical implications of dietary therapies for chronic kidney disease may warrant further research. ________________________________________________________________________________ New trial could dampen enthusiasm for increased water intake in CKD Effect of Coaching to Increase Water Intake on Kidney Function Decline in Adults With Chronic Kidney Disease: The CKD WIT Randomized Clinical Trial Clark, et al. JAMA. 2018;319(18):1870-1879 If asked to name something ‘good for the kidneys’, most patients would probably say ‘drinking more water’. However, the evidence for this advice is limited to animal and observational studies and it is not known whether high fluid intake might preserve renal function in those with CKD. To answer this question, Clark, et al. randomised 661 participants with stage 3 CKD and albuminuria to regular coaching to target a fluid intake 1-1.5L higher than their baseline amount and provided with urine colour charts to encourage dilute urine. At the end of 12 months, compared to the control group, those in the water intake group increased their urine output by an average of 0.6L per day (95%CI 0.5-0.7; P<0.001), had a lower serum co-peptin level (-2.2pmol/l [95%CI -3.9 - -0.5; P =0.01) and higher urinary creatinine clearance (3.6ml/min [95%CI 0.8-6.4]; P=0.01). Despite this, there was no significant difference in change in eGFR (-0.3ml/min/1.73m2 [95%CI -1.8-1.2]; P=0.74]). Accounting for the patients in the control group who also had an increase in urine volume in a per-protocol analysis produced a similar result. While disappointing, it may be that a greater separation in urine volume or a longer period of follow up is required for the benefits of increased fluid intake to become apparent. Further work is expected in this field and it may be premature to put aside the water bottles just yet.

A preview of this infographic is available below, and can be downloaded to the left.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings